Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.61 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.61 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.60 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.59 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.59 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.59 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.59 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.59 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.59 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.59 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.59 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.59 |
| ▸ | KDR | P35968 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 9/20 | 0.58 |
| ▸ | NPC1 | O15118 | 8/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.58 |
| ▸ | POLB | P06746 | 2/20 | 0.58 |
| ▸ | MAPT | P10636 | 2/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL845872 | 0.91 | TRPV1 (0.71) | TRPV1HDAC4KDM4EKDRRAB9A | |
| SCHEMBL27894588 | 0.86 | MAP4K4 (0.53) | TRPV1HDAC4HDAC1KDM4EHDAC3 | |
| SCHEMBL8568774 | 0.85 | KDM4E (0.67) | TRPV1HDAC4HDAC1KDM4EHDAC3 | |
| SCHEMBL14784253 | 0.84 | SYK (0.47) | TRPV1HDAC4HDAC1KDM4EHDAC3 | |
| SCHEMBL846497 | 0.84 | CNR2 (0.47) | TRPV1HDAC4HDAC1KDM4EHDAC3 | |
| SCHEMBL12101564 | 0.83 | HDAC4 (0.45) | TRPV1HDAC4HDAC1KDM4EHDAC3 | |
| SCHEMBL28237660 | 0.83 | CNR2 (0.47) | TRPV1HDAC4HDAC1KDM4EHDAC3 | |
| SCHEMBL4071391 | 0.83 | MALT1 (0.55) | TRPV1HDAC4HDAC1KDM4EHDAC3 | |
| SCHEMBL257596 | 0.82 | NPC1 (0.65) | RAB9ANPC1SMN1; SMN2POLBMAPT | |
| SCHEMBL2730100 | 0.82 | NAMPT (0.49) | TRPV1HDAC4HDAC1KDM4EHDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110603253-B | Heteroaryl phenylamino quinolines and analogs | 拜耳公司 | 2023-01-20 | — | — | CN | disclosed |
| WO-2020182929-A1 | SUBSTITUTED UREAS AND DERIVATIVES AS NEW ANTIFUNGAL AGENTS | BAYER AKTIENGESELLSCHAFT (DE) | 2020-09-17 | — | — | WO | disclosed |
| EP-2613775-B1 | N-HYDROXY-BENZAMIDES FOR THE TREATMENT OF CANCER | HOFFMANN LA ROCHE (CH) | 2014-07-30 | — | — | EP | disclosed |
| US-8716285-B2 | N-hydroxy-benzamids for the treatment of cancer | HOFFMANN-LA ROCHE INC. (US) | 2014-05-06 | — | — | US | disclosed |
| US-8293768-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-10-23 | — | — | US | disclosed |
| US-20120065204-A1 | NOVEL N-HYDROXY-BENZAMIDS FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2012-03-15 | — | — | US | disclosed |
| WO-2012031993-A1 | NOVEL N-HYDROXY-BENZAMIDES FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2012-03-15 | — | — | WO | disclosed |
| US-20120004164-A1 | ORGANIC COMPOUNDS | XENON PHARMACEUTICALS INC. (CA) | 2012-01-05 | — | — | US | disclosed |
| US-8063084-B2 | Heterocyclic compounds suitable for the treatment of diseases related to elevated lipid levels | NOVARTIS AG (CH) | 2011-11-22 | — | — | US | disclosed |
| US-20100233116-A1 | ORGANIC COMPOUNDS | XENON PHARMACEUTICALS INC. (CA) | 2010-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100233116-A1 | ORGANIC COMPOUNDS | SCD, SCD5, FADS2 | TRPV1 501/4885HDAC4 82/4885HDAC1 17/4885 |
| US-20120004164-A1 | ORGANIC COMPOUNDS | SCD, SCD5, FADS2 | TRPV1 382/4885HDAC4 330/4885HDAC1 136/4885 |
| US-20120065204-A1 | NOVEL N-HYDROXY-BENZAMIDS FOR THE TREATMENT OF CANCER | HNMT, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HRAS | TRPV1 2668/4885HDAC4 24/4885HDAC1 36/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.